Edward M. Basile - 20 May 2026 Form 4 Insider Report for TransMedics Group, Inc. (TMDX)

Reporting relationship: Director
Issuer ticker: TMDX
Reported as of: 20 May 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 22 May 2026, 16:15:11 UTC
Prior SEC filing: 31 Oct 2025
Source filing: View source filing
Reporting owner signature: By: /s/ Gerardo Hernandez, Attorney-in-Fact

Key filing fact

Edward M. Basile filed Form 4 for TransMedics Group, Inc. (TMDX) on 22 May 2026.

Key facts

This page summarizes Edward M. Basile's Form 4 filing for TransMedics Group, Inc. (TMDX).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 22 May 2026, 16:15.

Change

Previous filing in this sequence was filed on 31 Oct 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001773661 Primary reporting owner

Basile Edward M

Relationship: Director
Address: C/O TRANSMEDICS GROUP, INC., 200 MINUTEMAN ROAD, ANDOVER
Signature: By: /s/ Gerardo Hernandez, Attorney-in-Fact
Signature date: 22 May 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

TMDX transaction

Common Stock

Award

Transaction value
Shares: +2,922
Change %: +102%
Price: $0.000000^*
Shares after: 5,788
Date: 20 May 2026
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 1 footnote

Footnote F1

Consists of 2,922 restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock.